Potential Weakness: The potential weakness of the studies is that they were of relatively short duration (≤24 weeks) and so the long-term effects of insulin aspart in CSII cannot be assessed.

and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same ...

Biphasic insulin aspart 30/70 was administered once, twice or three-times daily, depending on the patient's needs; the dose was adjusted individually as required, based on the physician's decision ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).